Home / Health / Bezisterim Trial Reveals Two Long COVID Endotypes
Bezisterim Trial Reveals Two Long COVID Endotypes
10 Nov
Summary
- Two distinct Long COVID endotypes identified in ADDRESS-LC trial.
- High-inflammatory endotype improved cognition; low-myeloid improved fatigue.
- Bezisterim showed differential treatment responses based on endotype.
New biomarker findings from the Phase 2 ADDRESS-LC trial presented at the 2026 RECOVER-TLC Hybrid Workshop suggest two distinct Long COVID endotypes. These endotypes are associated with different patient responses to bezisterim treatment.
Patients with a high-inflammatory endotype experienced improvements in objective cognitive impairment. In contrast, individuals with a low-myeloid endotype showed greater improvements in fatigue and post-exertional malaise (PEM).
These exploratory biomarker insights highlight the importance of aligning clinical endpoints with patient biology to avoid obscuring meaningful treatment effects when analyzing diverse patient populations together.
BioVie Inc. announced these findings, emphasizing that the identification of these distinct biological profiles could inform future Long COVID study designs. Bezisterim demonstrated a comparable safety and tolerability profile to placebo in the trial.
Additional data is slated for presentation at the 4th Long COVID International Conference 2026 in Nice, France, from November 12-13, 2026. There are currently no FDA-approved treatment options for Long COVID.
